Ionis Pharmaceuticals (IONS) announced that it intends to offer, subject to market conditions and other factors, $700M aggregate principal amount of convertible senior notes due 2030 in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Ionis expects to use the net proceeds from the offering for repurchases of its 0% convertible senior notes due 2026 from time to time, including potential repurchases of the 2026 notes concurrently with the pricing of the notes in the offering, and the repayment of any remaining 2026 notes at maturity, and any remaining net proceeds for general corporate purposes.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Ionis Pharmaceuticals’ Olezarsen: Promising Phase 3 Results and Blockbuster Potential Justify Buy Rating
- Ionis Pharmaceuticals Reports Positive Phase 3 Study Results
- Ionis Pharmaceuticals price target raised to $110 from $100 at H.C. Wainwright
- Promising Potential of Ionis Pharmaceuticals’ Olezarsen Drives Buy Rating
- Ionis Pharmaceuticals announces Phase 3 CORE, CORE2 met primary endpoint